ClinicalTrials.gg
CompletedNCT02652260Updated Feb 7, 2025Results posted

Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)

A Phase 2 interventional study of Doravirine, Tenofovir, Lamivudine - Blinded and Doravirine, Tenofovir, Lamivudine - Open-Label in HIV-1 and Central Nervous System, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate a switch from fixed dose combination (FDC) treatment with ATRIPLA\^TM for 12 weeks prior to screening to FDC treatment with Doravirine, Tenofovir, Lamivudine (MK-1439A) in virologically-suppressed, human immunodeficiency virus type 1 (HIV-1)-infected participants. The primary hypothesis is that switching from ATRIPLA\^TM to Doravirine, Tenofovir, Lamivudine results in a lower proportion of participants with at least one CNS toxicity of at least Grade 2 intensity at Week 12 than continuation of ATRIPLA\^TM treatment.

02

Conditions studied

  • HIV-1
  • Central Nervous System
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • is taking ATRIPLA™, generic versions of ATRIPLA™, or the components of ATRIPLA™ (EFV,TDF plus emtricitabine),
  • has documentation of -1 ribonucleic acid (RNA) \< 50 copies/mL during the 12 weeks prior to screening while on ATRIPLA™.
  • has plasma HIV-1 RNA levels below the limits of quantification (BLoQ) at the screening visit.
  • if genotyped prior to starting initial antiretroviral regimen, must have no known resistance to any of the study agents
  • has at least one EFV-associated CNS toxicities of Grade 2 or worse intensity both at the time of screening and at Study Day 1
  • is highly unlikely to become pregnant or to impregnate a partner
  • To be eligible for study extension 1, participants from Immediate Switch Group (ISG) must have completed Study Week 24, and benefited from study participation; participants from Deferred Switch Group (DSG) must have completed Study Week 36, and benefited from study participation as determined by the investigator
  • To be eligible for study extension 2, participants from ISG must have completed Study Week 120, and benefited from study participation; participants from DSG must have completed Study Week 132, and benefited from study participation as determined by the investigator

Exclusion criteria

Exclusion Criteria:

  • is a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence.
  • has ongoing Grade 4 CNS toxicity during screening period that requires a prompt change in ART
  • has been treated for a viral infection other than -1, such as , with an agent that is active against HIV-1 including, but not limited to, adefovir, emtricitabine, entecavir, lamivudine or tenofovir.
  • has documented or known resistance to study drugs including doravirine, lamivudine, and/or tenofovir
  • has participated in, or anticipates participating in a study with an compound/device within 30 days prior to signing
  • has used systemic therapy or immune modulators or anticipates using them within 30 days prior to this study
  • requires or anticipates requiring any of the prohibited medications
  • has significant or other to any of the components of the study drugs
  • has a current (active) diagnosis of acute hepatitis due to any cause.
  • has evidence of decompensated liver disease manifested by the presence of or a history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other signs or symptoms of advanced liver diseases, or has liver cirrhosis and a Class C score or Pugh-Turcotte (CPT) score > 9.
  • is pregnant, breastfeeding, or expecting to conceive.
  • female is expecting to donate eggs (at any time during the study) or male is expecting to donate sperm (at any time during the study).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Immediate Switch to Doravirine, Tenofovir, Lamivudine

    Participants on a baseline regimen of ATRIPLA™ for at least 12 weeks prior to screening will be switched to blinded doravirine, tenofovir, lamivudine orally, once daily for 12 weeks, followed by open-label doravirine, tenofovir, lamivudine orally, once daily for an additional 12 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label doravirine, tenofovir, lamivudine for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 216 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 312 weeks.

    Drug: Doravirine, Tenofovir, Lamivudine - Blinded · Drug: Doravirine, Tenofovir, Lamivudine - Open-Label · Drug: Placebo to ATRIPLA™

  • Experimental
    Deferred Switch to Doravirine, Tenofovir, Lamivudine

    Participants will continue on their ongoing ATRIPLA™ regimen orally, once daily for 12 weeks, followed by open-label doravirine, tenofovir, lamivudine orally, once daily for 24 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label doravirine, tenofovir, lamivudine for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 228 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 324 weeks.

    Drug: Doravirine, Tenofovir, Lamivudine - Open-Label · Drug: ATRIPLA^TM · Drug: Placebo to Doravirine, Tenofovir, Lamivudine

Interventions

  • A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the Blinded period

    Also known as: MK-1439A

  • A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period; also an additional 96 weeks during the Open-Label extension period 1; a maximum total duration of treatment of 228 weeks during the Open-Label extension period 2; and a maximum total duration of treatment of 324 weeks during the Open-Label extension period 3.

    Also known as: MK-1439A

  • DrugATRIPLA^TM

    A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period

  • DrugPlacebo to ATRIPLA™

    A single placebo to ATRIPLA™ tablet administered orally, once daily for 12 weeks during the Blinded period

  • DrugPlacebo to Doravirine, Tenofovir, Lamivudine

    A single placebo to doravirine, tenofovir, lamivudine tablet administered orally, once daily for 12 weeks during the Blinded period

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least One Central Nervous System (CNS) Toxicity of at Least Grade 2 Intensity at Week 12

    A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. Percentage of participants with at least one CNS toxicity of Grade 2 or higher were recorded, based on the last observation carried forward (LOCF) approach.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants With at Least One CNS Toxicity of at Least Grade 2 Intensity at Week 4

    A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. Percentage of participants with at least one CNS toxicity of Grade 2 or higher were recorded, based on the last observation carried forward (LOCF) approach.

    Time frame: Week 4

  2. Change From Baseline in CNS Toxicity Score at Week 4

    A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. The CNS toxicity score was calculated by summing across all 10 CNS toxicities and converting the sum to a percentage of the maximum possible sum of intensities (10 x 3 = 30). A positive change from baseline score indicates worsening symptoms. A negative change from baseline score indicates improvement in symptoms.

    Time frame: Baseline and Week 4

  3. Change From Baseline in CNS Toxicity Score at Week 12

    A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. The CNS toxicity score was calculated by summing across all 10 CNS toxicities and converting the sum to a percentage of the maximum possible sum of intensities (10 x 3 = 30). A positive change from baseline score indicates worsening symptoms. A negative change from baseline score indicates improvement in symptoms.

    Time frame: Baseline and Week 12

  4. Percentage of Participants With at Least One CNS Toxicity of at Least Grade 2 Intensity at Time of Switch, and at 24 Weeks Post-switch for the Combined Treatment Groups

    A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. For the Immediate Switch Group (ISG) time of switch was study Day 1, and week 24 post-switch was week 24. For the Delayed Switch Group (DSG) time of switch was study week 12, and week 24 post-switch was week 36.

    Time frame: Baseline (time of switch) and 24 weeks post-switch

  5. CNS Toxicity Scores at Time of Switch, and at 24 Weeks Post-switch for the Combined Treatment Groups

    A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). The CNS toxicity score was calculated by summing across all 10 CNS toxicities and converting the sum to a percentage of the maximum possible sum of intensities (10 x 3 = 30). A higher CNS score indicates worse symptoms. A positive change in CNS score indicates worsening symptoms. A negative change indicates improvement in symptoms. For the ISG time of switch was study Day 1, and week 24 post-switch was week 24. For the DSG time of switch was study week 12, and week 24 post-switch was week 36.

    Time frame: Baseline (time of switch) and 24 weeks post-switch

  6. Change From Baseline in Fasting Lipids at Week 12

    Blood was collected under fasting conditions on Day 1 and on week 12 in order to determine the concentration of the following lipids: low-density lipoprotein (LDL) cholesterol; Non high-density lipoprotein (HDL) cholesterol; cholesterol; HDL cholesterol; and triglyceride.

    Time frame: Baseline (study Day 1) and study week 12

  7. Change in Fasting Lipids Between Time of Switch and Week 24 Post-switch for the Combined Treatment Groups

    Blood was collected under fasting conditions at time of switch and 24 weeks post-switch in order to determine the change from baseline of the following lipids: low-density lipoprotein (LDL) cholesterol; Non high-density lipoprotein (HDL) cholesterol; cholesterol; HDL cholesterol; and triglyceride. For the ISG time of switch was study Day 1, and week 24 post-switch was week 24. For the DSG time of switch was study week 12, and week 24 post-switch was week 36.

    Time frame: Baseline (time of switch) and 24 weeks post-switch

  8. Percentage of Participants With HIV-1 RNA <50 and <40 Copies/ml at Week 24 Post-switch for the Combined Treatment Groups

    Blood was collected under fasting conditions at 24 weeks post-switch in order to determine the HIV-1 RNA. For the ISG week 24 post-switch was week 24. For the DSG week 24 post-switch was week 36.

    Time frame: 24 weeks post-switch

  9. Change From Time of Switch to Week 24 Post Switch in CD4 T-cell Count for the Combined Treatment Groups

    Blood was collected at time of switch and at 24 weeks post-switch in order to determine the CD4 T-cell count. For the ISG time of switch was study Day 1, and week 24 post-switch was week 24. For the DSG time of switch was study week 12, and week 24 post-switch was week 36.

    Time frame: Baseline (time of switch) and 24 weeks post-switch

  10. Number of Participants With One or More Adverse Events (AEs) Through Study Week 12

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

    Time frame: Up to Week 12

  11. Number of Participants With One or More Drug-related AEs Through Study Week 12

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE was determined by the investigator to be related to the drug.

    Time frame: Up to Week 12

  12. Number of Participants With One or More Serious Adverse Events (SAEs) Through Study Week 12

    A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose.

    Time frame: Up to Week 12

  13. Number of Participants With One or More Drug-related SAEs Through Study Week 12

    A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose. A drug-related SAE was determined by the investigator to be related to the drug.

    Time frame: Up to Week 12

  14. Number of Participants Who Discontinued Treatment Due to an AE Through Study Week 12

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

    Time frame: Up to Week 12

  15. Number of Participants With One or More AEs for the Combined Treatment Groups 24 Weeks After the Switch

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.

    Time frame: 24 weeks post-switch

  16. Number of Participants With One or More Drug-related AEs for the Combined Treatment Groups 24 Weeks After the Switch

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE was determined by the investigator to be related to the drug. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.

    Time frame: 24 weeks post-switch

  17. Number of Participants With One or More SAEs for the Combined Treatment Groups 24 Weeks After the Switch

    A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.

    Time frame: 24 weeks post-switch

  18. Number of Participants With One or More Drug-related SAEs for the Combined Treatment Groups 24 Weeks After the Switch

    A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose. A drug-related SAE was determined by the investigator to be related to the drug. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.

    Time frame: 24 weeks post-switch

  19. Number of Participants Who Discontinued Treatment Due to an AE for the Combined Treatment Groups 24 Weeks After the Switch

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.

    Time frame: 24 weeks post-switch

07

Results

Posted Aug 29, 2019

Participant flow

Base Study
Participant flow — Base Study
MilestoneImmediate Switch to MK-1439ADeferred Switch to MK-1439A
Started4343
Switched over to mk-1439a042
Completed4341
Not completed02
Withdrew: Pregnancy01
Withdrew: Withdrawal by subject01
Study Extension 1 (Open-Label)
Participant flow — Study Extension 1 (Open-Label)
MilestoneImmediate Switch to MK-1439ADeferred Switch to MK-1439A
Started4341
Completed3934
Not completed47
Withdrew: Withdrawal by subject12
Withdrew: Pregnancy11
Withdrew: Lack of efficacy11
Withdrew: Availability of study drug locally11
Withdrew: Adverse event02
Study Extension 2 (Open-Label)
Participant flow — Study Extension 2 (Open-Label)
MilestoneImmediate Switch to MK-1439ADeferred Switch to MK-1439A
Started3933
Completed1719
Not completed2214
Withdrew: Adverse event10
Withdrew: Availability of study drug locally1813
Withdrew: Lost to follow-up10
Withdrew: Non-compliance with study drug10
Withdrew: Pregnancy11
Study Extension 3 (Open-Label)
Participant flow — Study Extension 3 (Open-Label)
MilestoneImmediate Switch to MK-1439ADeferred Switch to MK-1439A
Started1719
Completed108
Not completed711
Withdrew: Physician decision710
Withdrew: Pregnancy01

Outcome measures

PrimaryPercentage of Participants With at Least One Central Nervous System (CNS) Toxicity of at Least Grade 2 Intensity at Week 12

A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. Percentage of participants with at least one CNS toxicity of Grade 2 or higher were recorded, based on the last observation carried forward (LOCF) approach.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Central Nervous System (CNS) Toxicity of at Least Grade 2 Intensity at Week 12
Percentage of participantsImmediate Switch to MK-1439ADeferred Switch to MK-1439A
Percentage of Participants With at Least One Central Nervous System (CNS) Toxicity of at Least Grade 2 Intensity at Week 1241.937.2
Statistical analysis
  • Immediate Switch to MK-1439A vs Deferred Switch to MK-1439A · Miettinen and Nurminen · p = 0.331 · Estimated difference: 4.65 · 95% CI -15.92 to 24.85
SecondaryPercentage of Participants With at Least One CNS Toxicity of at Least Grade 2 Intensity at Week 4

A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. Percentage of participants with at least one CNS toxicity of Grade 2 or higher were recorded, based on the last observation carried forward (LOCF) approach.

Time frame:
Week 4
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One CNS Toxicity of at Least Grade 2 Intensity at Week 4
Percentage of participantsImmediate Switch to MK-1439ADeferred Switch to MK-1439A
Percentage of Participants With at Least One CNS Toxicity of at Least Grade 2 Intensity at Week 446.565.1
Statistical analysis
  • Immediate Switch to MK-1439A vs Deferred Switch to MK-1439A · Estimated difference: -18.61 · 95% CI -38.14 to 2.51
SecondaryChange From Baseline in CNS Toxicity Score at Week 4

A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. The CNS toxicity score was calculated by summing across all 10 CNS toxicities and converting the sum to a percentage of the maximum possible sum of intensities (10 x 3 = 30). A positive change from baseline score indicates worsening symptoms. A negative change from baseline score indicates improvement in symptoms.

Time frame:
Baseline and Week 4
Reported as:
Mean · Percentage of maximum score
Change From Baseline in CNS Toxicity Score at Week 4
Percentage of maximum scoreImmediate Switch to MK-1439ADeferred Switch to MK-1439A
Change From Baseline in CNS Toxicity Score at Week 4-17.6 (-23.4 to -11.8)-15.6 (-22.0 to -9.2)
Statistical analysis
  • Immediate Switch to MK-1439A vs Deferred Switch to MK-1439A · Estimated difference: -2.0 · 95% CI -10.5 to 6.5
SecondaryChange From Baseline in CNS Toxicity Score at Week 12

A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. The CNS toxicity score was calculated by summing across all 10 CNS toxicities and converting the sum to a percentage of the maximum possible sum of intensities (10 x 3 = 30). A positive change from baseline score indicates worsening symptoms. A negative change from baseline score indicates improvement in symptoms.

Time frame:
Baseline and Week 12
Reported as:
Mean · Percentage of maximum score
Change From Baseline in CNS Toxicity Score at Week 12
Percentage of maximum scoreImmediate Switch to MK-1439ADeferred Switch to MK-1439A
Change From Baseline in CNS Toxicity Score at Week 12-18.1 (-22.9 to -13.3)-21.7 (-27.9 to -15.5)
Statistical analysis
  • Immediate Switch to MK-1439A vs Deferred Switch to MK-1439A · Estimated difference: 3.6 · 95% CI -4.1 to 11.3
SecondaryPercentage of Participants With at Least One CNS Toxicity of at Least Grade 2 Intensity at Time of Switch, and at 24 Weeks Post-switch for the Combined Treatment Groups

A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). Mild = symptom is noticeable but does not interfere with normal activities; moderate = symptom has some impact on normal activities; severe = symptom prevents conduct of normal activities. For the Immediate Switch Group (ISG) time of switch was study Day 1, and week 24 post-switch was week 24. For the Delayed Switch Group (DSG) time of switch was study week 12, and week 24 post-switch was week 36.

Time frame:
Baseline (time of switch) and 24 weeks post-switch
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One CNS Toxicity of at Least Grade 2 Intensity at Time of Switch, and at 24 Weeks Post-switch for the Combined Treatment Groups
Percentage of participantsCombined Treatment Groups: Time of SwitchCombined Treatment Groups: Week 24 Post-Switch
Percentage of Participants With at Least One CNS Toxicity of at Least Grade 2 Intensity at Time of Switch, and at 24 Weeks Post-switch for the Combined Treatment Groups68.630.2
Statistical analysis
  • Combined Treatment Groups: Time of Switch vs Combined Treatment Groups: Week 24 Post-Switch · Difference in percentage: -38.4 · 95% CI -51.2 to -23.8
SecondaryCNS Toxicity Scores at Time of Switch, and at 24 Weeks Post-switch for the Combined Treatment Groups

A questionnaire was used to solicit for CNS toxicity based on the following 10 events: dizziness; depression/low mood; insomnia/sleeplessness; anxiety/nervousness; confusion; impaired concentration/attention; headache; somnolence/daytime sleepiness; aggressive mood/behavior; and abnormal dreams. Participants were asked to rate the intensity for each of the 10 events as none (Grade 0), mild (Grade 1), moderate (Grade 2), or severe (Grade 3). The CNS toxicity score was calculated by summing across all 10 CNS toxicities and converting the sum to a percentage of the maximum possible sum of intensities (10 x 3 = 30). A higher CNS score indicates worse symptoms. A positive change in CNS score indicates worsening symptoms. A negative change indicates improvement in symptoms. For the ISG time of switch was study Day 1, and week 24 post-switch was week 24. For the DSG time of switch was study week 12, and week 24 post-switch was week 36.

Time frame:
Baseline (time of switch) and 24 weeks post-switch
Reported as:
Mean · Percentage of maximum score
CNS Toxicity Scores at Time of Switch, and at 24 Weeks Post-switch for the Combined Treatment Groups
Percentage of maximum scoreCombined Treatment Groups: Time of SwitchCombined Treatment Groups: Week 24 Post-Switch
CNS Toxicity Scores at Time of Switch, and at 24 Weeks Post-switch for the Combined Treatment Groups24.2 (20.5 to 27.9)10.7 (8.7 to 12.8)
Statistical analysis
  • Combined Treatment Groups: Time of Switch vs Combined Treatment Groups: Week 24 Post-Switch · Mean difference (final values): -13.4 · 95% CI -16.8 to -10.1
SecondaryChange From Baseline in Fasting Lipids at Week 12

Blood was collected under fasting conditions on Day 1 and on week 12 in order to determine the concentration of the following lipids: low-density lipoprotein (LDL) cholesterol; Non high-density lipoprotein (HDL) cholesterol; cholesterol; HDL cholesterol; and triglyceride.

Time frame:
Baseline (study Day 1) and study week 12
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Lipids at Week 12
mg/dLImmediate Switch to MK-1439ADeferred Switch to MK-1439A
LDL Cholesterol-10.78 ± 15.85-1.88 ± 14.88
Non-HDL Cholesterol-14.08 ± 17.17-0.37 ± 16.51
Cholesterol-22.14 ± 19.490.00 ± 18.04
HDL Cholesterol-8.05 ± 7.740.37 ± 7.91
Triglyceride-21.19 ± 43.377.10 ± 38.55
Statistical analysis
  • Immediate Switch to MK-1439A vs Deferred Switch to MK-1439A · Difference estimate: -9.02 · 95% CI -15.69 to -2.35
  • Immediate Switch to MK-1439A vs Deferred Switch to MK-1439A · Difference estimate: -13.57 · 95% CI -20.79 to -6.35
  • Immediate Switch to MK-1439A vs Deferred Switch to MK-1439A · Difference estimate: -21.42 · 95% CI -29.63 to -13.21
  • Immediate Switch to MK-1439A vs Deferred Switch to MK-1439A · Difference estimate: -8.18 · 95% CI -11.76 to -4.60
  • Immediate Switch to MK-1439A vs Deferred Switch to MK-1439A · Difference estimate: -22.18 · 95% CI -38.52 to -5.84
SecondaryChange in Fasting Lipids Between Time of Switch and Week 24 Post-switch for the Combined Treatment Groups

Blood was collected under fasting conditions at time of switch and 24 weeks post-switch in order to determine the change from baseline of the following lipids: low-density lipoprotein (LDL) cholesterol; Non high-density lipoprotein (HDL) cholesterol; cholesterol; HDL cholesterol; and triglyceride. For the ISG time of switch was study Day 1, and week 24 post-switch was week 24. For the DSG time of switch was study week 12, and week 24 post-switch was week 36.

Time frame:
Baseline (time of switch) and 24 weeks post-switch
Reported as:
Mean · mg/dL
Change in Fasting Lipids Between Time of Switch and Week 24 Post-switch for the Combined Treatment Groups
mg/dLCombined Treatment Groups
LDL Cholesterol-10.97 ± 17.15
Non-HDL Cholesterol-13.18 ± 19.82
Cholesterol-20.91 ± 20.19
HDL Cholesterol-7.72 ± 9.53
Triglyceride-12.99 ± 46.61
SecondaryPercentage of Participants With HIV-1 RNA <50 and <40 Copies/ml at Week 24 Post-switch for the Combined Treatment Groups

Blood was collected under fasting conditions at 24 weeks post-switch in order to determine the HIV-1 RNA. For the ISG week 24 post-switch was week 24. For the DSG week 24 post-switch was week 36.

Time frame:
24 weeks post-switch
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <50 and <40 Copies/ml at Week 24 Post-switch for the Combined Treatment Groups
Percentage of participantsCombined Treatment Groups
< 50 copies/mL95.3 (88.4 to 98.7)
< 40 copies/mL95.3 (88.4 to 98.7)
SecondaryChange From Time of Switch to Week 24 Post Switch in CD4 T-cell Count for the Combined Treatment Groups

Blood was collected at time of switch and at 24 weeks post-switch in order to determine the CD4 T-cell count. For the ISG time of switch was study Day 1, and week 24 post-switch was week 24. For the DSG time of switch was study week 12, and week 24 post-switch was week 36.

Time frame:
Baseline (time of switch) and 24 weeks post-switch
Reported as:
Mean · cells/mm^3
Change From Time of Switch to Week 24 Post Switch in CD4 T-cell Count for the Combined Treatment Groups
cells/mm^3Combined Treatment Groups
Change From Time of Switch to Week 24 Post Switch in CD4 T-cell Count for the Combined Treatment Groups70.4 (35.9 to 104.8)
SecondaryNumber of Participants With One or More Adverse Events (AEs) Through Study Week 12

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With One or More Adverse Events (AEs) Through Study Week 12
ParticipantsImmediate Switch to MK-1439ADeferred Switch to MK-1439A
Number of Participants With One or More Adverse Events (AEs) Through Study Week 123434
SecondaryNumber of Participants With One or More Drug-related AEs Through Study Week 12

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE was determined by the investigator to be related to the drug.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With One or More Drug-related AEs Through Study Week 12
ParticipantsImmediate Switch to MK-1439ADeferred Switch to MK-1439A
Number of Participants With One or More Drug-related AEs Through Study Week 12149
SecondaryNumber of Participants With One or More Serious Adverse Events (SAEs) Through Study Week 12

A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With One or More Serious Adverse Events (SAEs) Through Study Week 12
ParticipantsImmediate Switch to MK-1439ADeferred Switch to MK-1439A
Number of Participants With One or More Serious Adverse Events (SAEs) Through Study Week 1200
SecondaryNumber of Participants With One or More Drug-related SAEs Through Study Week 12

A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose. A drug-related SAE was determined by the investigator to be related to the drug.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With One or More Drug-related SAEs Through Study Week 12
ParticipantsImmediate Switch to MK-1439ADeferred Switch to MK-1439A
Number of Participants With One or More Drug-related SAEs Through Study Week 1200
SecondaryNumber of Participants Who Discontinued Treatment Due to an AE Through Study Week 12

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Treatment Due to an AE Through Study Week 12
ParticipantsImmediate Switch to MK-1439ADeferred Switch to MK-1439A
Number of Participants Who Discontinued Treatment Due to an AE Through Study Week 1200
SecondaryNumber of Participants With One or More AEs for the Combined Treatment Groups 24 Weeks After the Switch

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.

Time frame:
24 weeks post-switch
Reported as:
Count of participants · Participants
Number of Participants With One or More AEs for the Combined Treatment Groups 24 Weeks After the Switch
ParticipantsCombined Treatment Groups
Number of Participants With One or More AEs for the Combined Treatment Groups 24 Weeks After the Switch71
SecondaryNumber of Participants With One or More Drug-related AEs for the Combined Treatment Groups 24 Weeks After the Switch

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE was determined by the investigator to be related to the drug. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.

Time frame:
24 weeks post-switch
Reported as:
Count of participants · Participants
Number of Participants With One or More Drug-related AEs for the Combined Treatment Groups 24 Weeks After the Switch
ParticipantsCombined Treatment Groups
Number of Participants With One or More Drug-related AEs for the Combined Treatment Groups 24 Weeks After the Switch18
SecondaryNumber of Participants With One or More SAEs for the Combined Treatment Groups 24 Weeks After the Switch

A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.

Time frame:
24 weeks post-switch
Reported as:
Count of participants · Participants
Number of Participants With One or More SAEs for the Combined Treatment Groups 24 Weeks After the Switch
ParticipantsCombined Treatment Groups
Number of Participants With One or More SAEs for the Combined Treatment Groups 24 Weeks After the Switch1
SecondaryNumber of Participants With One or More Drug-related SAEs for the Combined Treatment Groups 24 Weeks After the Switch

A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that results in any of the following: death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; is associated with an overdose. A drug-related SAE was determined by the investigator to be related to the drug. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.

Time frame:
24 weeks post-switch
Reported as:
Count of participants · Participants
Number of Participants With One or More Drug-related SAEs for the Combined Treatment Groups 24 Weeks After the Switch
ParticipantsCombined Treatment Groups
Number of Participants With One or More Drug-related SAEs for the Combined Treatment Groups 24 Weeks After the Switch0
SecondaryNumber of Participants Who Discontinued Treatment Due to an AE for the Combined Treatment Groups 24 Weeks After the Switch

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol - specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. For the ISG 24 week post-switch was week 24; for the DSG week 24 post-switch was week 36.

Time frame:
24 weeks post-switch
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Treatment Due to an AE for the Combined Treatment Groups 24 Weeks After the Switch
ParticipantsCombined Treatment Groups
Number of Participants Who Discontinued Treatment Due to an AE for the Combined Treatment Groups 24 Weeks After the Switch0

Adverse events

Collected over Up to approximately 326 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Immediate Switch to MK-1439A (Day 1 to Week 24)0/43 (0%)0/43 (0%)29/43 (67.4%)
Deferred Switch to MK-1439A (Day 1 to Week 12)0/43 (0%)0/43 (0%)25/43 (58.1%)
Deferred Switch to MK-1439A (Week 12-36)0/42 (0%)1/42 (2.4%)26/42 (61.9%)
Immediate Switch to MK-1439A EXT 1 (Week 24-120)0/43 (0%)6/43 (14%)31/43 (72.1%)
Deferred Switch to MK-1439A EXT 1 (Week 36-132)0/41 (0%)2/41 (4.9%)33/41 (80.5%)
Immediate Switch to MK-1439A EXT 2 (Week 120-216)0/39 (0%)3/39 (7.7%)—
Deferred Switch to MK-1439A EXT 2 (Week 132-228)0/33 (0%)1/33 (3%)—
Immediate Switch to MK-1439A EXT 3 (Week 216-312)0/17 (0%)2/17 (11.8%)—
Deferred Switch to MK-1439A EXT 3 (Week 228-324)0/19 (0%)0/19 (0%)—
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventImmediate Switch to MK-1439A (Day 1 to Week 24)Deferred Switch to MK-1439A (Day 1 to Week 12)Deferred Switch to MK-1439A (Week 12-36)Immediate Switch to MK-1439A EXT 1 (Week 24-120)Deferred Switch to MK-1439A EXT 1 (Week 36-132)Immediate Switch to MK-1439A EXT 2 (Week 120-216)Deferred Switch to MK-1439A EXT 2 (Week 132-228)Immediate Switch to MK-1439A EXT 3 (Week 216-312)Deferred Switch to MK-1439A EXT 3 (Week 228-324)
Head injuryInjury, poisoning and procedural complications0/430/430/420/430/410/390/331/170/19
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/430/430/420/430/410/390/331/170/19
CystoceleReproductive system and breast disorders0/430/430/420/430/411/390/331/170/19
AppendicitisInfections and infestations0/430/430/420/430/410/391/330/170/19
Wound sepsisInfections and infestations0/430/430/420/430/410/391/330/170/19
Stab woundInjury, poisoning and procedural complications0/430/430/420/430/411/390/330/170/19
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/430/430/421/430/411/390/330/170/19
Pneumonia haemophilusInfections and infestations0/430/430/420/431/410/390/330/170/19
Suicide attemptPsychiatric disorders0/430/430/420/431/410/390/330/170/19
Spinal compression fractureInjury, poisoning and procedural complications0/430/431/420/430/410/390/330/170/19
Most frequent other events
Showing 10 of 26
Most frequent other events
EventImmediate Switch to MK-1439A (Day 1 to Week 24)Deferred Switch to MK-1439A (Day 1 to Week 12)Deferred Switch to MK-1439A (Week 12-36)Immediate Switch to MK-1439A EXT 1 (Week 24-120)Deferred Switch to MK-1439A EXT 1 (Week 36-132)Immediate Switch to MK-1439A EXT 2 (Week 120-216)Deferred Switch to MK-1439A EXT 2 (Week 132-228)Immediate Switch to MK-1439A EXT 3 (Week 216-312)Deferred Switch to MK-1439A EXT 3 (Week 228-324)
HeadacheNervous system disorders11/437/433/428/4314/41————
AnxietyPsychiatric disorders2/432/437/427/4311/41————
InsomniaPsychiatric disorders8/437/436/425/4310/41————
SomnolenceNervous system disorders6/433/435/429/437/41————
DepressionPsychiatric disorders3/431/434/425/438/41————
Upper respiratory tract infectionInfections and infestations4/436/432/424/437/41————
AggressionPsychiatric disorders3/432/432/424/437/41————
ArthralgiaMusculoskeletal and connective tissue disorders7/431/432/424/433/41————
DizzinessNervous system disorders7/435/435/425/435/41————
Confusional statePsychiatric disorders1/431/433/426/436/41————

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Immediate Switch to MK-1439ADeferred Switch to MK-1439ATotal
Mean41.8 ± 11.941.6 ± 11.241.7 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Immediate Switch to MK-1439ADeferred Switch to MK-1439ATotal
Female191736
Male242650
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Immediate Switch to MK-1439ADeferred Switch to MK-1439ATotal
Hispanic or Latino415
Not Hispanic or Latino394281
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Immediate Switch to MK-1439ADeferred Switch to MK-1439ATotal
American Indian or Alaska Native000
Asian314
Native Hawaiian or Other Pacific Islander000
Black or African American252348
White121931
More than one race303
Unknown or Not Reported000
CNS Toxicity Percentage Of Maximum Score
CNS Toxicity Percentage Of Maximum Score(Percentage of maximum score)Immediate Switch to MK-1439ADeferred Switch to MK-1439ATotal
Mean32.9 ± 16.537.1 ± 19.035.0 ± 17.8
Fasting Lipids
Fasting Lipids(mg/dL)Immediate Switch to MK-1439ADeferred Switch to MK-1439ATotal
LDL Cholesterol98.67 ± 35.2899.54 ± 33.5799.13 ± 34.15
Non-HDL Cholesterol118.73 ± 36.93117.76 ± 37.83118.22 ± 37.16
Cholesterol178.11 ± 36.39173.02 ± 36.62175.44 ± 36.37
HDL Cholesterol59.38 ± 14.5855.27 ± 14.0057.22 ± 14.34
Triglyceride107.49 ± 65.6491.39 ± 39.4399.03 ± 53.73
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Nelson M, Winston A, Hill A, Mngqibisa R, Bassa A, Orkin C, Rassool M, Rodgers A, Teal V, Kumar S, Teppler H. Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. AIDS. 2021 Apr 1;35(5):759-767. doi: 10.1097/QAD.0000000000002804. PubMed 33587439 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Aug 2018, 29 months.

Results were first posted in Aug 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2016
First posted
Jan 11, 2016
StartActual
Mar 4, 2016
Primary completionActual
Aug 14, 2018
CompletionActual
Feb 7, 2024
Results first posted
Aug 29, 2019
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02652260
Responsible party
Sponsor
First posted
Jan 11, 2016
Start date
Mar 4, 2016
Primary completion
Aug 14, 2018
Completion
Feb 7, 2024
Results posted
Aug 29, 2019
Last update
Feb 7, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doravirine

Start the discussion